Cabazitaxel XRP6258

DRUG7 trials

Conditions

Gastric CancerNeoplasm MalignantProstate CancerProstate Cancer Metastatic

Phase 1

Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy

CompletedNCT01497964

SanofiGastric Cancer

Start: 2011-12-31End: 2013-05-31Updated: 2014-11-10

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

CompletedNCT01511536

SanofiProstate Cancer

Start: 2012-03-31End: 2014-12-31Updated: 2016-07-28

Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

CompletedNCT01527929

SanofiNeoplasm Malignant

Start: 2012-04-30End: 2013-11-30Updated: 2013-12-04

Phase 2

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

TerminatedNCT02379390

SanofiProstate Cancer Metastatic

Start: 2015-06-17End: 2018-05-10Updated: 2019-06-21

Phase 4

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

CompletedNCT02074137

SanofiProstate Cancer Metastatic

Start: 2014-07-31End: 2016-03-31Updated: 2016-06-02

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

CompletedNCT02441894

SanofiProstate Cancer

Start: 2015-04-30End: 2016-11-30Updated: 2017-01-24

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

CompletedNCT02485691

SanofiProstate Cancer Metastatic

Start: 2015-11-09End: 2021-03-15Updated: 2022-05-27

2025-11-04

Abstract 1145: Morphological evaluation of chromosomal instability in circulating tumor cells and prediction of taxane resistance in metastatic prostate cancer: a prespecified sub-analysis of the CARD trial

Cancer Research2025-04-21

An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

BMC Health Services Research2022-07-142 citations

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

2021-08-2420 citations

Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.

2021-07-1516 citations

Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m<sup>2</sup> every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2021-05-201 citations

CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.

Journal of Clinical Oncology2021-02-203 citations

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

Japanese Journal of Clinical Oncology2021-02-165 citations

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.

2020-09-1145 citations

CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.

Journal of Clinical Oncology2020-05-202 citations

Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.

Journal of Clinical Oncology2020-05-202 citations

PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY

The Journal of Urology2020-04-011 citations

Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.

Journal of Clinical Oncology2020-02-194 citations

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

New England Journal of Medicine2019-09-30634 citations

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.

2019-08-019 citations

Eine randomisierte, offene, Multizenterstudie zum Einsatz von Cabazitaxel versus einem Androgenrezeptor (AR)-gerichteten Präparat (Abirateron oder Enzalutamid) bei Patienten mit mCRPC nach Vorbehandlung mit Docetaxel und frühem Nicht-Ansprechen nach AR-gerichtetem Präparat (CARD) – Studie AP 97/17 der AUO

Aktuelle Urologie2018-05-22

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

2017-01-0120 citations

Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.

Journal of Clinical Oncology2015-03-013 citations

A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens (GASTANA).

Journal of Clinical Oncology2014-01-20

Cabazitaxel XRP6258

Sponsors

Conditions

Phase 1

Phase 2

Phase 4

Related Papers